Who Paid My Doc
Pedmark
Drug cisplatin-induced ototoxicity
NDC 73077-010-01
General payments
$230,844
Research payments
$0
Through program year 2024, $230,844 in general payments and $0 in research payments were reported against Pedmark (cisplatin-induced ototoxicity).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | General | $185,312 | 1,107 |
| 2023 | General | $45,532 | 242 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2024.
The top 5 of 41 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.
The top 5 of 37 states; each share is of general payments naming this product in 2024 where a state was reported.
Records
1,349 generalEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.